Actualización en el tratamiento de la coinfección por VIH y VHC en pacientes adultos

  1. Rial Crestelo, David
  2. Torralba González de Suso, Miguel
  3. Rodríguez Zapata, Manuel
Revista:
RIECS: Revista de Investigación y Educación en Ciencias de la Salud

ISSN: 2530-2787

Año de publicación: 2019

Volumen: 4

Número: 2

Páginas: 71-83

Tipo: Artículo

DOI: 10.37536/RIECS.2019.4.2.163 DIALNET GOOGLE SCHOLAR lock_opene_Buah editor

Otras publicaciones en: RIECS: Revista de Investigación y Educación en Ciencias de la Salud

Resumen

El presente artículo es una revisión sobre el tratamiento del VHC en pacientes infectados por el VIH. Se aborda brevemente el contexto epidemiológico, la interacción existente entre ambos virus, y la historia natural e inmunopatogenia del VHC. Posteriormente se analizan las estrategias históricas (que incluían el interferón pegilado) y las actuales con los nuevos agentes antivirales directos. Se profundiza en las indicaciones, el concepto de respuesta viral sostenida, la eficacia, la toxicidad, y el tratamiento en situaciones especiales como la infección aguda por VHC o el trasplante hepático. Por último, se aborda la evolución de la fibrosis hepática, el trasplante hepático, el riesgo de hepatocarcinoma y el impacto poblacional de la curación de la infección por VHC.

Referencias bibliográficas

  • Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet (London, England). 2016;388(10049):1081-1088. doi:10.1016/S0140-6736(16)30579-7.
  • Internet. UNAIDS. Data 2017. United Nations Program HIV/AIDS.
  • Berenguer J, Rivero A, Jarrín I, et al. Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. Open Forum Infect Dis. 2016;3:1-9.
  • Mallet V, Vallet-Pichard A, Pol S. The impact of human immunodeficiency virus on viral hepatitis. Liver Int. 2011;31 Suppl 1:135-139. doi:10.1111/j.1478-3231.2010.02394.x.
  • Sherman KE, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease: An update. Hepatology. 2015;62(6):1871-1882. doi:10.1002/hep.28150.
  • Ingiliz P, Rockstroh JK. Natural history of liver disease and effect of hepatitis C virus on HIV disease progression. Curr Opin HIV AIDS. 2015;10(5):303-308. doi:10.1097/COH.0000000000000187.
  • Valle Tovo C, Alves de Mattos A, Ribeiro de Souza A, et al. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver Int. 2007;27(1):40-46. doi:10.1111/j.1478-3231.2006.01344.x.
  • Echeverria N, Moratorio G, Cristina J, Moreno P. Hepatitis C virus genetic variability and evolution. World J Hepatol. 2015;7(6):831-845. doi:10.4254/wjh.v7.i6.831.
  • Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429-2438. doi:10.1056/NEJMcp1006613.
  • Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-68. doi:10.1016/j.jhep.2014.07.012.
  • Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky J-M. Structural biology of hepatitis C virus. Hepatology. 2004;39(1):5-19. doi:10.1002/hep.20032.
  • Sharma G, Raheja H, Das S. Hepatitis C virus: Enslavement of host factors. IUBMB Life. 2018;70(1):41-49. doi:10.1002/iub.1702.
  • Dedania B, Wu GY. Dermatologic Extrahepatic Manifestations of Hepatitis C. J Clin Transl Hepatol. 2015;3(2):127-133. doi:10.14218/JCTH.2015.00010.
  • Nicot F, Alric L, Barange K, et al. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy. J Med Virol. 2011;83(3):437-444. doi:10.1002/jmv.21976.
  • Scotto G, Fazio V, Palumbo E, Cibelli DC, Saracino A, Angarano G. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients. New Microbiol. 2005;28(1):23-29.
  • Santos Gil I, Sanz Sanz J. [Treatment with interferon and ribavirin of chronic hepatitis C in HIV-infected patients]. An Med Interna. 2004;21(8):369-372.
  • Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011;54(5):1538-1546. doi:10.1002/hep.24549.
  • Poordad F, McCone JJ, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206. doi:10.1056/NEJMoa1010494.
  • Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416. doi:10.1056/NEJMoa1012912.
  • De Meyer S, Dierynck I, Ghys A, et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology. 2012;56(6):2106-2115. doi:10.1002/hep.25962.
  • Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet (London, England). 2010;376(9742):705-716. doi:10.1016/S0140-6736(10)60934-8.
  • Kondili LA, Romano F, Rolli FR, et al. Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort. Hepatology. 2017;66(6):1814-1825. doi:10.1002/hep.29399.
  • Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353-361. doi:10.1001/jama.2014.7734.
  • Molina J-M, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet (London, England). 2015;385(9973):1098-1106. doi:10.1016/S0140-6736(14)62483-1.
  • Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313(12):1232-1239. doi:10.1001/jama.2015.1373.
  • Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. Vol 373. United States; 2015. doi:10.1056/NEJMoa1501315.
  • Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223-1231. doi:10.1001/jama.2015.1328.
  • Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. Vol 373. United States; 2015. doi:10.1056/NEJMoa1503153.
  • Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. lancet HIV. 2015;2(8):e319-27. doi:10.1016/S2352-3018(15)00114-9.
  • Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet (London, England). 2015;385(9973):1075-1086. doi:10.1016/S0140-6736(14)61795-5.
  • Wyles D, Brau N, Kottilil S, et al. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clin Infect Dis. 2017;65(1):6-12. doi:10.1093/cid/cix260.
  • Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018;67(7):1010-1017. doi:10.1093/cid/ciy220.
  • Back D, Khoo S. HEP Drug Interactions. https://www.hep-druginteractions.org/checker.
  • EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511. doi:10.1016/j.jhep.2018.03.026.
  • Schmid P, Bregenzer A, Huber M, et al. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. PLoS One. 2015;10(9):e0138838. doi:10.1371/journal.pone.0138838.
  • Perez-Latorre L, Rivero-Juarez A, Hontanon V, et al. Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C. Open forum Infect Dis. 2016;3(4):ofw212. doi:10.1093/ofid/ofw212.
  • Merchante N, Tellez F, Rivero-Juarez A, et al. Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis. BMC Infect Dis. 2015;15:557. doi:10.1186/s12879-015-1291-3.
  • Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int. 2015;35(1):30-36. doi:10.1111/liv.12576.
  • Juanbeltz R, Perez-Garcia A, Aguinaga A, et al. Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. PLoS One. 2018;13(12):e0208554. doi:10.1371/journal.pone.0208554.
  • Lombardi A, Mondelli MU. Hepatitis C: Is eradication possible? Liver Int. 2019;39(3):416-426. doi:10.1111/liv.14011.
  • Cipriano LE, Goldhaber-Fiebert JD. Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence. MDM policy Pract. 2018;3(1):2381468318776634. doi:10.1177/2381468318776634.
  • Greenaway C, Makarenko I, Chakra CNA, et al. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health. 2018;15(9). doi:10.3390/ijerph15092013.
Fuente de los datos: Dialnet